Qiagen Buys DxS, Boasts "Deepest" Personalized Medicine Testing Pipeline
This article was originally published in The Gray Sheet
Executive Summary
Qiagen is boasting the "deepest" pipeline of molecular diagnostics for personalized medicine after acquiring test maker DxS for $95 million, plus up to $35 million in milestone payments
You may also be interested in...
News In Brief
Cardinal Health makes $2 billion acquisition; partnerships in diagnostics, mobile health announced; more news.
Qiagen Buys Cellestis For QuantiFeron “Pre-Molecular” Diagnostics
Qiagen plans to incorporate Cellestis’ QuantiFeron “pre-molecular” diagnostics technology into its own automated and mobile testing platforms after acquiring the firm for $355 million in a deal announced April 3.
Qiagen Buys Cellestis For QuantiFeron “Pre-Molecular” Diagnostics
Qiagen plans to incorporate Cellestis’ QuantiFeron “pre-molecular” diagnostics technology into its own automated and mobile testing platforms after acquiring the firm for $355 million in a deal announced April 3.